摘要
目的探讨不同剂量促红细胞生成素对维持性血液透析者C反应蛋白的影响。方法对42例维持性血液透析者随机分为小剂量组(n=21)和大剂量组(n=21)。小剂量组促红细胞生成素(r Hu EPO)以每周2次,每次3 000 U皮下注射.大剂量组则为每周1次,每次10 000 U皮下注射,于透析前,透析后和透析后4周,8周,12周测定患者的C反应蛋白(CRP)、血红蛋白红(Hb)细胞比积(Hct)等指标进行回顾性分析。结果 r Hu EPO治疗维持性血液透析者可显著降低C反应蛋白,且大剂量组r Hu EPO起效快,对C反应蛋白影响更明显,值得临床广泛推广应用。结论 r Hu EPO治疗维持性血液透析者安全有效,随着使用时间延长,大剂量组疗效更佳。动态监测C反应蛋白可以指导维持性血液透析者r Hu EPO的用量。
Objective To investigate the effect of erythropoietin（EPO） dosage on C-reactive protein（CRP） of patients who maintain on hemodialysis.Methods 42 patients on maintenance hemodialysis were randomized into low dosage（L,n = 21） and high dosage（H,n = 21） groups.The L group received 3,000 U EPO subcutaneously twice weekly.The H group received 1,000 U EPO subcutaneously once weekly.Measures including CRP,hemoglobin（Hb） and hematocrit（Hct） before hemodialysis,week 4,8 and 12 after hemodialysis were determined and analyzed retrospectively.Results EPO therapy in patients on maintenance hemodialysis significantly reduced levels of CRP.The H group had faster onset and more remarkable effect on CRP,indicating high dosage deserves further clinical application.Conclusions EPO therapy is safe and efficacious for patients on maintenance hemodialysis.The efficacy is better when high dosage is used with longer duration.Dynamic monitoring of CRP could be used as guidance for the EPO dosage for patients on maintenance hemodialysis.
出处
《航空航天医学杂志》
2015年第4期403-404,共2页
Journal of Aerospace medicine
